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To the Editor: Hypertension is the commonest chronic disease
occurring among adult South Africans.1,2 Rational prescribing
and the safe use of drugs are important in the management of
hypertensive patients since they are on chronic medication.3
The choice of antihypertensive agent(s) is equally important
because drug costs contribute up to 90% of the treatment costs
for hypertension.4 There are apparently no reports on the
management of hypertension in the Eastern Cape.1,2,5,6 We
therefore analysed prescriptions for antihypertensive drugs in
order to establish the drug utilisation patterns and the quality
of prescribing in the private health sector, and the extent to
which South African hypertension treatment guidelines 7,8 are
followed in Umtata. 
We did a retrospective analysis of all prescriptions for
antihypertensives between 1 January and 31 December 2000 at
Umtata Pharmacy, the largest community pharmacy in Umtata.
The pharmacy keeps all prescriptions served, hence we had
access to all prescriptions for the whole year. We used a
purpose-designed form to note the number of drugs, name(s)
of drug(s) (brand/generic), form of payment, and whether or
not the following were stated: diagnosis, dose, dosage form,
duration of treatment and dosing interval. 
There were 411 prescriptions for antihypertensives during
the year 2000. Of these, 222 (54%) were paid for by medical aid,
187 (45.5%) by cash, while form of payment was not stated for
2 prescriptions (0.5%). The overall average number of drugs
per prescription was 2.39 (range 1 - 8), 2.63 for medical aid
patients (range 1 - 8), and 2.11 for cash-paying patients (range 
1 - 7); the form of payment significantly influenced the number
of drugs per prescription (p < 0.001). In 9.9% of the
prescriptions 5 or more drugs were included. In 88.3% of
prescriptions only brand drug names were used, compared
with 5.4% that used generic names exclusively. Most
prescriptions were incomplete, for instance the diagnosis was
not stated in 84.9%, in 21.7% the duration of treatment was not
fully stated, and in 22.9% the dose was not properly stated.
Table I shows the distribution of antihypertensive drugs by
class. Single antihypertensive drug  prescriptions constituted
53.8%, 2 agents 39.1%, 3 agents 6.1% and 4 antihypertensive
agents 1% of the total. Fixed drug combinations constituted
only 8.5% of the prescriptions. Sixty-seven per cent of the
combinations included at least 1 diuretic.
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Table I. Distribution of prescribed antihypertensive agents by
group
Group % of total*
Diuretics 38.5
ACE inhibitors 23.5
Ca-channel blockers 20.4
Beta-blockers 10.0
Centrally acting 2.1
Angiotensin receptor blockers 1.9
Combined alpha/beta-blockers 1.7
Alpha-blockers 1.3
Vasodilators 0.5
Reserpine 0.2
* Expressed as a percentage of all prescribed agents.
ACE = angiotensin converting enzyme; Ca = calcium.
Table II. Comparative retail costs for some antihypertensive
agents
Cost of 1 month’s  
Drug supply (Rand)  
Atenolol (100 mg daily)
Atenolol (generic) 19.84
Tenormin 249.10
Ten-Bloka 90.12
Captopril (25 mg t.d.s)
Captopril (generic) 109.10
Capoten 313.84
Captomax 132.21
Indapamide (2.5 mg daily)
Indapamide (generic) 70.99
Dapamax 79.61
Indalix 79.50
Natrilix 134.43
Enalapril (10 mg daily)
Enalapril (generic) 131.25
Renitec 164.16
Nifedipine (10 mg t.d.s.)
Nifedipine (generic) 179.32
Vascard 179.46
Cardilat 181.12
Adalat 477.20
Perindopril (4 mg daily)
Perindopril (generic) 122.76
Coversyl 204.62
Hydrochlorothiazide (25 mg daily)
Hydrochlorothiazide (generic) 2.05
Dichlotride 39.20
Urirex 4.90
Propranolol (40 mg t.d.s)
Propranolol (generic) 29.07
Pur-Bloka 81.90
Inderal 340.28
Furosemide (20 mg daily)
Furosemide (generic) 34.50
Lasix 89.74
Puresis 29.55
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The most frequently prescribed diuretics were indapamide
(45.1%), furosemide (18.9%), hydrochlorothiazide (18.4%) and
amiloride (12.7%); 29.9% of diuretics were prescribed as
monotherapy. Of the angiotensin converting enzyme (ACE)
inhibitors 31.5% were monotherapy, compared with 9.5% of the
calcium-channel blockers and 54% of the beta-blockers. Among
b-blockers, atenolol accounted for 49.2%, propranolol 44.4%,
and bisoprolol 6.4%; 174 prescriptions (42.3%) included non-
antihypertensive drugs. 
Table II compares the retail costs of generic and brand name
products for some of the widely used antihypertensives. 
The low percentage of generic prescribing, infrequent use of
fixed drug combinations, high number of incomplete
prescriptions, tendency to prescribe more drugs for medical aid
patients relative to those paying cash, and inconsistency of our
findings with available guidelines are troubling. For instance,
although diuretics were the commonest prescribed group,
indapamide, not hydrochlorothiazide, was the most popular,
and more than half the b-blockers were prescribed as
monotherapy. South African and international guidelines, on
the other hand, call for the use of a thiazide diuretic, followed
by b-blocker plus thiazide, but not b-blocker alone.7-10 The
guidelines discourage the use of propranolol in favour of
atenolol,8 yet we found that the two were prescribed equally.
Most prescriptions had no diagnosis, which limits the
evaluation of appropriateness of drug use. 11 The greater
prescription of brand name drugs relative to the generics, with
attendant higher costs, may result in irregular supply of drugs
and poor control of blood pressure.12,13 The polypharmacy
noted (10% with five or more items) raises the possibility of
irrational prescribing with higher likelihood of non-
compliance.14,15
Prescribers need to write complete prescriptions to ensure
proper and safe use of drugs. These concerns should be
addressed through CPD activities, which should incorporate
issues of treatment guidelines for common conditions such as
hypertension.
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To the Editor: Superficial siderosis (SS) is a rare but distinct
syndrome afflicting the central nervous system (CNS)
characterised by sensorineural deafness (SND), cerebellar
ataxia, dementia and myelopathy and caused by chronic
bleeding into the subarachnoid space.1-4 The source of this
bleeding is identified in only half of cases described.
Pathologically there is deposition of haemosiderin in those
parts of the CNS lying in close proximity to the cerebrospinal
fluid (CSF), including the subpial and subependymal margins.1
The haemosiderin deposition causes gliosis, neuronal loss and
demyelination.1 The peripheral nervous system is not affected.1
Hamill  first described this condition in 1908, and in 1995, 87
cases of superficial siderosis were reported in the literature
worldwide.1 It occurs more commonly in males (male/female
3:1) and has been described in patients with an age range of 
14 - 77 years.1 No specific racial predilection has been noted.  
We describe here a 58-year-old South African woman with SS
in whom no cause has been identified. As far as we are aware
there is no report of a case(s) of SS from South Africa.
Case presentation
A 58-year-old woman presented with a history of deafness and
gait disturbance. The deafness had started in the left ear 6
years before presentation, and within 6 months of onset it
Superficial siderosis — case report and review
